Landos Biopharma, Inc. (LABP)

Market Cap	69.28M
Revenue (ttm)	n/a
Net Income (ttm)	-21.94M
Shares Out	3.12M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,501
Open	22.84
Previous Close	22.36
Day's Range	22.21 - 22.84
52-Week Range	2.50 - 22.84
Beta	0.15
Analysts	Hold
Price Target	20.42 (-9.2%)
Earnings Date	May 10, 2024

About LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2021
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: LABP

Analyst Forecast

According to one analyst, the rating for LABP stock is "Hold" and the 12-month stock price forecast is $20.42.

Price Target

$20.42

(-9.20% downside)

Analyst Consensus: Hold